Recent Updates
Recently added Catalysts

ILS-920

Phase 1

Acute Ischemic Stroke | Small molecule | Neurology |Pfizer, Inc.|Last Updated: Feb 3, 2010

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindUNCONTROLLED
Total Trials1
Total Enrollment16
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00827190Study Evaluating Single Ascending Doses Of ILS-920PHASE1 COMPLETED 16 — — Feb 1, 2009Jul 1, 2009Feb 3, 2010 - —
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Safety based on vital sign evaluations, 12-lead ECGs, cardiac rhythm monitoring and routine lab tests.
48 hours after study drug administration
Secondary Endpoints
Pharmacokinetics will measure the extent and rate of Absorption, Distribution, Metabolism and Excretion of the drug in the body.
48 hours after study drug administration
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
1EXPERIMENTALILS-920
Interventions
NameTypeDescription
ILS-920DRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 50 Years
SexALL
Healthy VolunteersYes

Inclusion Criteria: * Men or women of nonchildbearing potential * Aged 18 to 50 years inclusive at screening. Exclusion Criteria: * Any significant cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease....

Unlock Eligibility Criteria